These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 32657634

  • 1. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of 177Lu-Nimotuzumab.
    Suman S, Priya R, Kameswaran M.
    Int J Radiat Biol; 2020 Sep; 96(9):1144-1156. PubMed ID: 32657634
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
    Chan C, Fonge H, Lam K, Reilly RM.
    Nucl Med Biol; 2020 Sep; 80-81():37-44. PubMed ID: 31706737
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase.
    Lin S, Yan Y, Liu Y, Gao CZ, Shan D, Li Y, Han B.
    Cell Biol Int; 2015 Feb; 39(2):146-51. PubMed ID: 25044496
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair.
    Qu YY, Hu SL, Xu XY, Wang RZ, Yu HY, Xu JY, Chen L, Dong GL.
    PLoS One; 2013 Feb; 8(8):e70727. PubMed ID: 23976954
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM.
    Prostate; 2009 Jan 01; 69(1):92-104. PubMed ID: 18942092
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. (131)I-Nimotuzumab - A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR.
    Kameswaran M, Samuel G, Dev Sarma H, Shinde SN, Dash A, Venkatesh M.
    Appl Radiat Isot; 2015 Aug 01; 102():98-102. PubMed ID: 26002276
    [Abstract] [Full Text] [Related]

  • 16. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
    Beckford Vera DR, Eigner S, Eigner Henke K, Leyva Montaña R, Melichar F, Beran M.
    Recent Results Cancer Res; 2013 Aug 01; 194():301-17. PubMed ID: 22918766
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
    Phaeton R, Jiang Z, Revskaya E, Fisher DR, Goldberg GL, Dadachova E.
    Cancer Med; 2016 Jan 01; 5(1):9-16. PubMed ID: 26625938
    [Abstract] [Full Text] [Related]

  • 19. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.
    Cancer Med; 2016 Mar 01; 5(3):486-99. PubMed ID: 26778701
    [Abstract] [Full Text] [Related]

  • 20. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu.
    Aghevlian S, Cai Z, Lu Y, Hedley DW, Winnik MA, Reilly RM.
    Mol Pharm; 2019 Feb 04; 16(2):768-778. PubMed ID: 30589553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.